Freyn et al. (2020) “A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice” Molecular Therapy.
DOI:10.1016/j.ymthe.2020.04.018
Read about Freyn et al. (2020) “A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice” Molecular Therapy.
Raj et al. (2020) “Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria” Nature.
DOI:10.1038/s41586-020-2220-1
Read about Raj et al. (2020) “Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria” Nature.
Marcos-Contreras (2020) “Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier” PNAS.
DOI: 10.1073/pnas.1912012117
Read about Marcos-Contreras (2020) “Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier” PNAS.
Willis et al. (2020) “Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice” Science Translational Medicine.
DOI: 10.1126/scitranslmed.aav5701
Read about Willis et al. (2020) “Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice” Science Translational Medicine.
Huysmans et al. (2019) “Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin” Molecular Therapy Nucleic Acids.
DOI: 10.1016/j.omtn.2019.08.001
Read about Huysmans et al. (2019) “Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin” Molecular Therapy Nucleic Acids.
Pardi et al. (2019) “Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques” Molecular Therapy Nucleic Acids.
DOI: 10.1016/j.omtn.2019.03.003
Read about Pardi et al. (2019) “Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques” Molecular Therapy Nucleic Acids.
Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Molecular Therapy.
DOI: 10.1016/j.ymthe.2019.03.003
Read about Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Molecular Therapy.
Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” Journal of Controlled Release.
DOI:10.1016/j.jconrel.2018.10.015
Read about Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” Journal of Controlled Release.
Read about Pardi et al. (2018) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies” Nature Communications.
Pardi et al. (2018) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine.
DOI:10.1084/jem.20171450
Read about Pardi et al. (2018) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine.
Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines.
DOI:10.1038/s41541-017-0032-6
Read about Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines.
Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
DOI:10.15252/emmm.201707678
Read about Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.